Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Modified-Release Drug Delivery Systems: Site-Targeted

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Design, synthesis and biological evaluation of 1-Aryl-5-(4-arylpiperazine-1-carbonyl)-1<i>H</i>-tetrazols as novel microtubule destabilizers.

Journal of enzyme inhibition and medicinal chemistry·2021

Same author

Titanium dioxide nanoparticles relieve biochemical dysfunctions of fifth-instar larvae of silkworms following exposure to phoxim insecticide.

Chemosphere·2012

Same author

Mechanisms of prostate atrophy after LHRH antagonist cetrorelix injection: an experimental study in a rat model of benign prostatic hyperplasia.

Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban·2012

Same author

Simulation and experimental investigation of structural dynamic frequency characteristics control.

Sensors (Basel, Switzerland)·2012

Same author

Chronic clomipramine treatment restores hippocampal expression of glial cell line-derived neurotrophic factor in a rat model of depression.

Journal of affective disorders·2012

Same author

Application of nanoLC-MS/MS to the shotgun proteomic analysis of the nematocyst proteins from jellyfish Stomolophus meleagris.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences·2012

Search research articles

Related Experiment Video

Updated: Jun 23, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Precision-Engineered PROTACs: Integrating Physical and Chemical Strategies for Targeted Cancer Therapy.

Hong Yao¹, Yujing Zhang², Haibo Zhao²

¹Department of Pharmacy, Shandong Provincial Maternal and Child Health Care Hospital Affiliated to Qingdao University, Jinan, Shandong, China.

Small (Weinheim an Der Bergstrasse, Germany)

|June 22, 2026

Summary

This summary is machine-generated.

Engineered proteolysis-targeting chimeras (PROTACs) offer enhanced safety and specificity for targeted protein degradation therapies. This review explores conditionally activatable PROTAC systems, improving their clinical potential in drug discovery.

Keywords:

PROTACs chemical control physical stimuli‐activatable precision therapeutics targeted degradation

More Related Videos

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

Related Experiment Videos

Last Updated: Jun 23, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

Area of Science:

Biochemistry
Molecular Biology
Pharmacology

Background:

Proteolysis-targeting chimeras (PROTACs) represent a novel therapeutic modality for targeted protein degradation.
Clinical application of PROTACs is hindered by challenges in target selectivity and potential off-target toxicity.
Conditional activation strategies are being developed to enhance PROTAC specificity and safety.

Purpose of the Study:

To review advancements in conditionally activatable PROTAC systems.
To analyze the molecular mechanisms, clinical applications, and limitations of engineered PROTACs.
To highlight the potential of controlled PROTAC platforms in drug discovery.

Main Methods:

Review of literature on physically regulated PROTACs (photo-, radiation-, ultrasound-activatable).
Analysis of chemically controlled PROTACs utilizing bioorthogonal conjugation.
Systematic examination of molecular mechanisms, clinical oncology applications, and safety profiles.

Main Results:

Two primary classes of engineered PROTACs are identified: physically regulated and chemically controlled systems.
These systems demonstrate improved specificity and safety profiles compared to conventional PROTACs.
Current applications are primarily focused on oncology, with ongoing evaluation of efficacy and safety.

Conclusions:

Conditionally activatable PROTACs show significant promise for improving targeted protein degradation therapies.
Further development of these precisely controlled platforms is crucial for enhancing clinical utility.
Engineered PROTACs are poised to advance modern drug discovery and treatment strategies.